Stock HAE HAEMONETICS CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Haemonetics Corporation

Equities

HAE

US4050241003

Market Closed - Nyse
Other stock markets
 04:00:02 2024-06-13 pm EDT 		5-day change 1st Jan Change
86.05 USD +0.14% Intraday chart for Haemonetics Corporation -1.52% +0.63%
Jun. 12 Haemonetics Shares Rise After Upgrade From Needham MT
Jun. 12 Needham Upgrades Haemonetics to Buy From Hold, Sets Price Target at $112 MT

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The company returns high margins, thereby supporting business profitability.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Sales forecast by analysts have been recently revised upwards.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.

Weaknesses

  • The company benefits from high valuations in earnings multiples.
  • For the last few months, analysts have been revising downwards their earnings forecast.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
HAEMONETICS CORPORATION Stock Haemonetics Corporation
+0.63% 4.38B
B-
ABBOTT LABORATORIES Stock Abbott Laboratories
-6.01% 182B
C+
MEDTRONIC PLC Stock Medtronic plc
-0.87% 108B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-4.86% 67.62B
A
DEXCOM, INC. Stock DexCom, Inc.
-8.28% 46.61B
B-
CENCORA, INC. Stock Cencora, Inc.
+13.07% 45.32B
B-
HOYA CORPORATION Stock Hoya Corporation
+4.26% 42.11B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+21.56% 31.17B
B
TERUMO CORPORATION Stock Terumo Corporation
+12.72% 25.66B
A-
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-4.50% 24.65B
A-
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. HAE Stock
  4. Ratings Haemonetics Corporation